David Johnston has left his role as chief financial officer of AVEO Pharmaceuticals to join ImmunoGen in the same role.
Johnston’s switch comes after more than six years at AVEO having joined the company from his role as senior VP of finance corporate planning and analysis at Genzyme.
Other previous roles include VP finance and chief financial officer of Genzyme Biosurgery.
In his new role, Johnston will head the financial operations of one of the leading biotechs working to develop antibody-drug conjugates in cancer, with ImmunoGen’s successes including the breast cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche.
“I am delighted to have Dave join ImmunoGen,” commented ImmunoGen’s CEO Daniel Junius.
“His depth of experience in both senior financial positions and in corporate planning makes Dave well-suited to help successfully advance the company to our next stages,” added Junius.